Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.

ABSTRACT:

Background

New screening technologies and vaccination against human papillomavirus (HPV), the necessary cause of cervical cancer, may impact optimal approaches to prevent cervical cancer. We evaluated the cost-effectiveness of alternative screening strategies to inform cervical cancer prevention guidelines in Norway.

Methods

We leveraged the primary epidemiologic and economic data from Norway to contextualise a simulation model of HPV-induced cervical cancer. The current cytology-only screening was compared with strategies involving cytology at younger ages and primary HPV-based screening at older ages (31/34+ years), an option being actively deliberated by the Norwegian government. We varied the switch-age, screening interval, and triage strategies for women with HPV-positi

SUBMITTER: Burger EA 

PROVIDER: S-EPMC3341862 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature